Yingluo Liu

506 total citations
11 papers, 153 citations indexed

About

Yingluo Liu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Yingluo Liu has authored 11 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Immunology. Recurrent topics in Yingluo Liu's work include Peptidase Inhibition and Analysis (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Ubiquitin and proteasome pathways (2 papers). Yingluo Liu is often cited by papers focused on Peptidase Inhibition and Analysis (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Ubiquitin and proteasome pathways (2 papers). Yingluo Liu collaborates with scholars based in China, United States and Norway. Yingluo Liu's co-authors include Li‐Jiang Xuan, Min Huang, Meiyu Geng, Chunpu Li, Xiaomin Wang, Xuewu Liang, Jiang Wang, Yu Zhou, Yingjie Zhang and Hong Liu and has published in prestigious journals such as Molecular Cell, Hepatology and Cancer Research.

In The Last Decade

Yingluo Liu

9 papers receiving 153 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yingluo Liu China 6 95 33 26 24 17 11 153
Stéphane Puyo France 6 83 0.9× 39 1.2× 19 0.7× 31 1.3× 22 1.3× 10 205
Anson Snow United States 7 124 1.3× 51 1.5× 54 2.1× 13 0.5× 22 1.3× 13 248
Xiujuan Yin China 9 86 0.9× 31 0.9× 36 1.4× 39 1.6× 13 0.8× 25 224
C. Scalbert France 5 115 1.2× 60 1.8× 33 1.3× 12 0.5× 10 0.6× 6 170
Yiwen Zhang China 9 102 1.1× 35 1.1× 26 1.0× 53 2.2× 24 1.4× 28 246
Wenqing Jia China 10 98 1.0× 52 1.6× 17 0.7× 21 0.9× 22 1.3× 21 220
Paulina Miziak Poland 8 151 1.6× 56 1.7× 44 1.7× 18 0.8× 21 1.2× 14 253
Her-Shyong Shiah Taiwan 8 86 0.9× 67 2.0× 42 1.6× 54 2.3× 32 1.9× 10 287
Lewei Zheng China 6 92 1.0× 54 1.6× 49 1.9× 12 0.5× 40 2.4× 19 255
F. M. Meng China 7 121 1.3× 38 1.2× 23 0.9× 8 0.3× 10 0.6× 10 196

Countries citing papers authored by Yingluo Liu

Since Specialization
Citations

This map shows the geographic impact of Yingluo Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingluo Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingluo Liu more than expected).

Fields of papers citing papers by Yingluo Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingluo Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingluo Liu. The network helps show where Yingluo Liu may publish in the future.

Co-authorship network of co-authors of Yingluo Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Yingluo Liu. A scholar is included among the top collaborators of Yingluo Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingluo Liu. Yingluo Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Liu, Yingluo, Xinyi Wang, Nishta Krishnan, et al.. (2025). Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles. Hepatology.
2.
Lu, Li‐Chun, Hao Zhuang, Yingluo Liu, et al.. (2025). PolyIC as an adjuvant outperforms anti-VEGF in combination with anti-PD-L1 therapy in mouse liver tumor models. Hepatology Communications. 9(9).
3.
Wang, Xinyi, Yingluo Liu, Shuo Zhang, et al.. (2024). Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss. Hepatology. 81(4). 1181–1196. 2 indexed citations
4.
Li, Yize, Shuai Tang, Yingluo Liu, et al.. (2024). Low‐Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells. Advanced Science. 11(11). e2304781–e2304781. 5 indexed citations
5.
Liu, Yingluo, Xiaojing Lan, Tao Yuan, et al.. (2024). Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non–Small Cell Lung Cancer. Cancer Research. 84(12). 1963–1977. 20 indexed citations
6.
Liu, Zhiwei, Shangwen Jiang, Bingbing Hao, et al.. (2023). A proteomic landscape of pharmacologic perturbations for functional relevance. Journal of Pharmaceutical Analysis. 14(1). 128–139. 1 indexed citations
7.
Ni, Nan, Haibo Li, Lanqi He, et al.. (2022). Structures and photocatalytic activities of bismuth oxyhalides nanoparticles developed by utilizing a simple reaction. Materials Science and Engineering B. 286. 116031–116031. 2 indexed citations
8.
Liu, Zhiwei, Yingluo Liu, Lili Qian, et al.. (2021). A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular Cell. 81(19). 4076–4090.e8. 35 indexed citations
9.
Liang, Xuewu, Shuai Tang, Xuyi Liu, et al.. (2021). Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. Journal of Medicinal Chemistry. 65(2). 1243–1264. 53 indexed citations
10.
Gao, Fei, Cong Xi, Huihui Li, et al.. (2019). Magnesium lithospermate B protects the endothelium from inflammation-induced dysfunction through activation of Nrf2 pathway. Acta Pharmacologica Sinica. 40(7). 867–878. 21 indexed citations
11.
Liu, Yingluo, et al.. (2019). Magnesium lithospermate B ameliorates microcirculation perfusion in rats by promoting vascular NO production via activating the PI3K/AKT pathway. Acta Pharmacologica Sinica. 40(8). 1010–1018. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphane Puyo Breakdown of academic impact, for papers by Anson Snow Breakdown of academic impact, for papers by Xiujuan Yin Breakdown of academic impact, for papers by C. Scalbert Breakdown of academic impact, for papers by Yiwen Zhang Breakdown of academic impact, for papers by Wenqing Jia Breakdown of academic impact, for papers by Paulina Miziak Breakdown of academic impact, for papers by Her-Shyong Shiah Breakdown of academic impact, for papers by Lewei Zheng Breakdown of academic impact, for papers by F. M. Meng
Rankless by CCL
2026